Asked by: Baroness Morris of Yardley (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they are developing to create a barcoded stock management system for medicines, akin to the EU's falsified medicines directive.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The European Union’s Falsified Medicines Directive’s (FMD) primary purpose was to help prevent falsified medicines from entering the legal supply chain through the introduction of safety features on the packaging and verification at certain points of the supply chain to confirm authenticity. The monitoring and management of shortages was not part of its original legal framework.
There are provisions in the Medicines and Medical Devices Act 2021 providing powers to enable the introduction of a similar system to the EU’s FMD’s ‘safety features’ and verification in the United Kingdom. However, the powers allow us to go beyond the FMD and use derived data from any system for other health related purposes. For example, to support the recall of medicines, to support patient care, research, policy development, and medicine supply, to prevent diversion and support patient access to medicines, and to counter fraud in primary care. Regulations would be needed to set out the details of any scheme, which would require consultation. Consideration is being given as to whether to consult on options for a potential UK system. Any consultation would be published in the usual way on the GOV.UK website.
Asked by: Baroness Morris of Yardley (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made on where medicine shortage sits on the Department for Health and Social Care risk register, and what is its corresponding 'RAG' rating.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The current Department’s High Level Risk Register categorises the risk to the continuity of medicine supply as amber-red after consideration of the mitigations available. This assessment is continuously reviewed in light of changing external risks to the supply of medicines and actions are taken to further reduce the risk of medicine shortages.
When medicine supply issues occur, we have established processes and systems in place to limit the impact on patients. This has been set out in detail in our recent publications Managing a robust and resilient supply of medicines and A guide to the systems and processes for managing medicines supply issues in England.
Asked by: Baroness Morris of Yardley (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps are being taken by NHS England to ensure that supplies of wigs contracted by the NHS offer a full range, including those appropriate for people of colour.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
During the process to renew what is now the current framework agreement, Wigs and Accessories, NHS Supply Chain conducted extensive engagement nationally to fully understand the provision and supply of wigs, and the requirements from both a National Health Service and supplier perspective. A significant challenge was that wig provision is predominantly conducted by the health and beauty industry, who were not familiar with public procurement law and healthcare framework tendering. NHS Supply Chain’s clinical and commercial teams worked closely with these industry groups to support their access to the wigs framework, to provide a wider range of products for NHS providers to access.
The current NHS Supply Chain framework will expire toward the end of 2025 and NHS Supply Chain’s teams are engaging with key stakeholders across the NHS to determine the future approach in this product area, with appropriateness for the wearer as one of the fundamental focus areas of consideration.
Asked by: Baroness Morris of Yardley (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of (1) the Voluntary Scheme for Branded Medicines Pricing and Access, and (2) the alternative statutory scheme, on the cost of homecare medicines services to the NHS.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
The Voluntary Scheme for Branded Medicines Pricing and Access and the alternative statutory scheme apply to medicines cost and not to service delivery.